Tgg-II-23A
Tgg-II-23A is a non-nucleoside HIV-1 reverse transcriptase inhibitor, with an IC50 of 136 μM against HIV-1 NL4-3 reverse transcriptase. Tgg-II-23A exhibits antiviral activity against wild-type HIV-1, but shows reduced activity against TIBO R82150 (HY-19111)-resistant HIV-1 strains carrying reverse transcriptase mutations. Tgg-II-23A does not inhibit the replication of HIV-2. Tgg-II-23A can be used in studies related to HIV-1 infection.
For research use only. We do not sell to patients.
- CAS No.: 153312-20-0
- Formula: C17H19NO2
- Molecular Weight:269.34
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[1]|
HIV-1 |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| CEM-SS | EC50 |
27 μM
|
Inhibition of HIV-1 RF replication in human CEM-SS T cells by XTT dye reduction assay after 6 days of incubation post-infection.
Inhibition of HIV-1 RF replication in human CEM-SS T cells by XTT dye reduction assay after 6 days of incubation post-infection.
|
7506510 |
| CEM-SS | CC50 |
550 μM
|
Cytotoxicity against human CEM-SS T cells by XTT dye reduction assay after 6 days of incubation post-infection.
Cytotoxicity against human CEM-SS T cells by XTT dye reduction assay after 6 days of incubation post-infection.
|
7506510 |
| MT2 | EC50 |
13 μM
|
Inhibition of HIV-1 (pNL4-3) infection in human MT-2 T cells by XTT dye reduction assay after 6 days of incubation post-infection.
Inhibition of HIV-1 (pNL4-3) infection in human MT-2 T cells by XTT dye reduction assay after 6 days of incubation post-infection.
|
7506510 |
| CEM-SS | EC50 |
>1000 μM
|
Inhibition of HIV-2 CBL-20 replication in human CEM-SS T cells by XTT dye reduction assay after 6 days of incubation post-infection, with no measurable inhibition observed at concentrations up to 1000 μM.
Inhibition of HIV-2 CBL-20 replication in human CEM-SS T cells by XTT dye reduction assay after 6 days of incubation post-infection, with no measurable inhibition observed at concentrations up to 1000 μM.
|
7506510 |
| CEM-SS | IC50 |
19.1 μM
|
Antiviral activity against CEM-SS cells infected with parental wild-type HIV-1 RF strain measured via XTT formazan production to determine cell viability relative to untreated control cells.
Antiviral activity against CEM-SS cells infected with parental wild-type HIV-1 RF strain measured via XTT formazan production to determine cell viability relative to untreated control cells.
|
095632029400500410 |
In Vitro
Tgg-II-23A (6 days) potently inhibits HIV-1 RF replication in vitro CEM-SS cells at non-cytotoxic concentrations[1].
Tgg-II-23A (800 μM) shows no activity against HIV-2 EHO infection in CEM-SS cells at 800 μM, confirming its HIV-1 selective antiviral profile[1].
Tgg-II-23A (1 h) directly inhibits purified recombinant wild-type HIV-1 NL4-3 reverse transcriptase in a cell-free biochemical assay using poly(rC):oligo(dG) template:primer, with an IC50 of 136 μM[1].
Tgg-II-23A (1 h) has drastically reduced inhibitory activity against Y181C mutant HIV-1 reverse transcriptase when assayed with poly(rA):oligo(dT) template:primer, with an IC50 of 10900 μM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:CEM-SS human T cells
-
Concentration:Serial dilutions
-
Incubation Time:6 day (post-infection); 4 h (XTT incubation)
-
Result:Inhibited HIV-1 RF replication with an EC50 of 27 μM, and produced 50% cytotoxicity in CEM-SS cells at a CC50 of 550 μM.
Returned an EC50 of 26 μM and a CC50 of 550 μM in additional replicate testing.
Chemical Information
-
CAS No. 153312-20-0
-
Molecular Weight 269.34
-
Formula C17H19NO2
-
SMILES
O=C1C=C(C=2C=CC=CC2C1(C3=NC(C)(C)CO3)C)C
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)